Core Insights - BrainsWay reported strong financial performance for Q4 and full-year 2025, with significant increases in operating income, revenue, and adjusted EBITDA, indicating robust growth and momentum in its Deep TMS business [1][3][4] Financial Performance - Q4 operating income reached approximately $1.9 million, up from $0.4 million year-over-year, while full-year operating income was approximately $4.3 million compared to $1.4 million in 2024 [1] - Q4 gross profit was $11.1 million, an increase from $8.5 million a year earlier, with a gross margin of 76% compared to 75% in the prior-year quarter [2] - Q4 revenue increased by 27% year-over-year to $14.5 million, with full-year revenue also rising 27% to $52.2 million compared to 2024 [3][7] - Full-year adjusted EBITDA was $7.0 million, representing 13% of revenue, which was at the top end of the company's guidance [1][4] Business Model and Strategy - The company is transitioning to a recurring leasing model, which has driven strong demand, shipping 95 Deep TMS systems in Q4 and growing its installed base to approximately 1,700 systems, a 26% increase from the prior year [6][8] - Remaining performance obligations grew to $70 million, reflecting a 43% increase from $49 million a year earlier, indicating strong future revenue visibility [8] Regulatory and Clinical Developments - The FDA expanded the Deep TMS label to include adolescents aged 15–21 with major depressive disorder, enhancing market access [5][17] - The company received a $2.5 million NIH grant for a clinical trial evaluating Deep TMS for alcohol use disorder, with recruitment goals set for over 200 patients [5][12] - BrainsWay is also working on a feasibility study for Alzheimer's disease and preparing an FDA submission based on data from U.S. depression patients with comorbid PTSD symptoms [13] Future Outlook - For 2026, the company guided revenue of $66 million to $68 million, representing year-over-year growth of 27% to 30%, with adjusted EBITDA expected to be between $12 million and $14 million [5][19] - The company remains debt-free with $68 million in cash and cash equivalents at year-end 2025, indicating a strong financial position [19]

Core Insights - BrainsWay Ltd. (BWAY) has expanded insurance coverage for its Deep TMS therapy in adolescent depression, indicating increased payer confidence in non-drug neurostimulation treatments and enhancing reimbursement visibility for younger patients [1][10]. Company Developments - Optum Behavioral Health has expanded its medical policy to include eligible adolescents, significantly increasing the number of covered lives and reinforcing the clinical acceptance of Deep TMS [2][10]. - The expansion of coverage is expected to strengthen BrainsWay by broadening its reimbursable patient base, improving utilization, and enhancing the lifetime value per system [4]. - BWAY's market capitalization stands at $334.8 million, with projected earnings growth of 100% for the current year [5]. Stock Performance - Following the announcement of the coverage expansion, BWAY shares rose by 10.1% at the market close, with a 53.6% increase over the past six months compared to the industry’s 5.5% growth and the S&P 500's 15.1% gain [3]. Industry Context - The global neuromodulation devices market is projected to grow from $5.80 billion in 2024 to $10.39 billion by 2030, with a CAGR of 8.51% from 2025 to 2030, driven by the rising incidence of chronic pain, neurological disorders, and mental health conditions [13]. - The expansion of Deep TMS coverage is particularly significant given the estimated 5 million adolescents aged 15-21 in the U.S. affected by major depression, a demographic with limited effective treatment options [12]. Future Prospects - BrainsWay is advancing its clinical footprint beyond depression with a new multicenter clinical trial for its next-generation Deep TMS 360 system aimed at treating Alcohol Use Disorder (AUD) [14].